|
Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from T1 Diabetes
Cyteir Therapeutics, Inc., a leader in the development of novel therapeutics based on the biology of DNA repair and synthetic lethality announced the publication of pre-clinical in vivo data demonstrating...
|
|
Vizient Inc to Participate in Antibiotic Resistance Panel at 2017 SOA Health Meeting
With the Centers for Disease Control and Prevention reporting at least two million people are infected with multi-drug resistant organisms annually, resulting in 23,000 deaths, and treatment costs in the billions...
|
|